|
Volumn 169, Issue 3, 2017, Pages 375-
|
Reducing Recurrence of C. difficile Infection
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BEZLOTOXUMAB;
CLOSTRIDIUM DIFFICILE TOXIN B;
MONOCLONAL ANTIBODY;
NEUTRALIZING ANTIBODY;
CLINICAL TRIAL (TOPIC);
CLOSTRIDIUM DIFFICILE INFECTION;
DRUG COST;
DRUG EFFICACY;
DRUG PROTEIN BINDING;
DRUG TARGETING;
HUMAN;
NONHUMAN;
PRIORITY JOURNAL;
RECURRENT INFECTION;
RISK REDUCTION;
SHORT SURVEY;
DRUG EFFECTS;
ENTEROCOLITIS, PSEUDOMEMBRANOUS;
INTESTINE;
INTESTINE FLORA;
PEPTOCLOSTRIDIUM DIFFICILE;
PHYSIOLOGY;
SECONDARY PREVENTION;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEUTRALIZING;
CLOSTRIDIUM DIFFICILE;
ENTEROCOLITIS, PSEUDOMEMBRANOUS;
GASTROINTESTINAL MICROBIOME;
HUMANS;
INTESTINES;
SECONDARY PREVENTION;
|
EID: 85018523685
PISSN: 00928674
EISSN: 10974172
Source Type: Journal
DOI: 10.1016/j.cell.2017.03.039 Document Type: Short Survey |
Times cited : (24)
|
References (10)
|